The treatment of varicose veins has reached another milestone with the FDA approval of the ClariVein® procedure – the first-ever non-thermal ablation treatment for enlarged veins caused by venous reflux disease. This treatment, created and distributed in the U.S. by Vascular Insights, was first approved for use in Europe and has been performed there for the past two years with tremendous results. In the U.S., ClariVein is currently covered by Medicare and is undergoing scrupulous studies to evaluate outcomes of efficacy and patient satisfaction.
Different approach. Same end result.
As with minimally invasive heat ablation procedures such as VNUS Closure™, ClariVein collapses and seals shut the diseased portion of the vein wall. The only difference is no heat is used. Instead, the sclerotherapy solution — sodium tetradecyl — is injected through an infusion catheter and dispersed as a tiny wire rotates along the vein walls. The combination of the rotating and the fluid break down the wall, collapsing it. Once this happens, blood is redirected through the deeper, healthier veins and healing of the affected area begins. Over time, the body naturally absorbs the collapsed vein.
No heat. No stick. No problem.
Because no heat is used, it is not necessary to numb the area with a local anesthetic. This means no pre-procedure sticks, which can be uncomfortable and anxiety-producing for some. It also eliminates the risk of thermal heat injury to surrounding areas – which means risk of nerve injury is eliminated as well.
Benefits of the ClariVein procedure
- Covered by Medicare
- Less discomfort and anxiety
- Reduced post procedure discomfort
- Minimal bruising
- No downtime
- Fast recovery
- Comparable results to VNUS Closure and other minimally invasive ablation procedures